Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Vincent C. Knick is active.

Publication


Featured researches published by Vincent C. Knick.


Investigational New Drugs | 1995

P-Glycoprotein mediated resistance to 5′-nor-anhydro-vinblastine (Navelbine®)

David J. Adams; Vincent C. Knick

SummaryNavelbine® (NVB, vinorelbine tartrate) is a semisyntheticVinca alkaloid in which the catharanthine moiety contains an eight-membered ring in place of the nine-membered ring that is present in all naturally occurring members of the vinblastine group. This modification selectively reduces interaction with anoxalvs mititotic microtubules and may account for the lower neurotoxicity with improved antitumor activity that has been observed in clinical trials with breast, lung and ovarian cancer. We were interested in whether the structural modification in NVB would also alter the drug resistance profile. Specifically, our aim was to determine whether NVB, like vinblastine (VBL), participates in P-glycoprotein (P-gp)-mediated multidrug resistance (MDR). NVB-resistant, murine P388 cells (P388/NVB), were derivedin vivo and used in conjunction with a battery of drug-resistant P388 cell linesin vivo and murine and human tumor cell linesin vitro to develop a resistance profile for NVB. P388/NVB bells were cross-resistant to drugs involved in MDR (doxorubicin, etoposide, amsacrine, vinblastine, vincristine and actinomycin D), but not to the alkylating agents, cyclophosphamide, carmustine, and cisplatin, or to the antimetabolites, 5-fluorouracil and methotrexate. P388/NVB cellular resistance to NVB was stable without drug pressure during continuous passagein vivo for more than ten weeks andin vitro for at least five weeks. These cells exhibited increased expression of P-gp, and a 30-fold level of resistance of NVBin vitro, which was completely reversable with verapamil. The MDR phenotype was confirmed in other tumor models. P388 tumors resistant to vinblastine, vincristine, doxorubicin, and etoposide were cross-resistant to NVBin vivo. Likewise, human KB carcinoma cells resistant to colchicine, MDA-A1R breast carcinoma cells resistant to doxorubicin, and murine B16/F10 melanoma cells transfected with the humanmdr1 gene were cross-resistant to NVBin vitro. Finally, P388 cells resistantin vivo to melphalan, a drug that does not participate in MDR, were cross-resistant to NVB. Therefore, cellular resistance to NVB, like otherVinca alkaloids, may arise by a P-glycoprotein-mediated MDR mechanism, but may also involve non-MDR mechanisms in cells that do not overexpress P-gp.


Cancer Research | 1993

In Vivo Antitumor Activity of 5-Fluorocytosine on Human Colorectal Carcinoma Cells Genetically Modified to Express Cytosine Deaminase

Brian E. Huber; Elizabeth A. Austin; Steven S. Good; Vincent C. Knick; Stephen Tibbels; Cynthia A. Richards


Cancer Research | 1995

Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line.

Quynh T. Trinh; Elizabeth A. Austin; Doris M. Murray; Vincent C. Knick; Brian E. Huber


Cancer Research | 1993

Biochemical and Cellular Pharmacology of 1843U89, a Novel Benzoquinazoline Inhibitor of Thymidylate Synthase

David S. Duch; Sheila D. Banks; Inderjit K. Dev; Scott Howard Dickerson; Robert Ferone; Louise S. Heath; Joan E. Humphreys; Vincent C. Knick; William Pendergast; Sara Singer; Gary K. Smith; Kathleen A. Waters; H. Robert Wilson


Journal of Medicinal Chemistry | 1990

[(1-Pyrenylmethyl)amino] alcohols, a new class of antitumor DNA intercalators. Discovery and initial amine side chain structure-activity studies

Kenneth W. Bair; Richard L. Tuttle; Vincent C. Knick; Michael Cory; David D. McKee


Journal of the National Cancer Institute | 1995

Vinorelbine Tartrate and Paclitaxel Combinations: Enhanced Activity Against In Vivo P388 Murine Leukemia Cells

Vincent C. Knick; Derek J. Eberwein; Charles Miller


Journal of Medicinal Chemistry | 1991

2-[(arylmethyl) amino]-2-methyl-1,3-propanediol DNA intercalators. An examination of the effects of aromatic ring variation on antitumor activity and DNA binding.

Kenneth W. Bair; Andrews Cw; Richard L. Tuttle; Vincent C. Knick; Michael Cory; David D. McKee


Cancer Research | 1990

Evaluation of Arylmethylaminopropanediols by a Novel in Vitro Pharmacodynamic Assay: Correlation with Antitumor Activity in Vivo

David J. Adams; Pamela J. Watkins; Vincent C. Knick; Richard L. Tuttle; Kenneth W. Bair


Cancer Research | 1983

In Vivo and in Vitro Antitumor Activity Expressed by Cells of Concomitantly Immune Mice

Richard L. Tuttle; Vincent C. Knick; Carolyn R. Stopford; Gerald Wolberg


Biochemical Pharmacology | 1994

Effect of purine synthesis inhibition on WiDr spheroids in vitro or on WiDr or colon 38 tumors in vivo: Complete growth inhibition but not regression

Marilyn Jansen; Michael Dykstra; Jacqueline I. Lee; Jeremy N. Stables; Peter Topley; Vincent C. Knick; Robert J. Mullin; David S. Duch; Gary K. Smith

Collaboration


Dive into the Vincent C. Knick's collaboration.

Top Co-Authors

Avatar

Brian E. Huber

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge